Aptorum Group Limited
| NASDAQ: APM | Healthcare / Biotechnology / United Kingdom |
| 2.64 | +0.0900 | +3.53% | Vol 119.38K | 1Y Perf -20.18% |
| Apr 16th, 2021 16:00 DELAYED |
| BID | 2.55 | ASK | 2.69 | ||
| Open | 2.53 | Previous Close | 2.55 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 22.00 | Analyst Rating | — — 0.00 | |
| Potential % | 733.33 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 45.42 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 89.79M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 11.32 | Earnings Date | 5th May 2021 |
Today's Price Range 2.402.64 | 52W Range 1.1614.23 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.01% | ||
| 1 Month | -20.72% | ||
| 3 Months | -20.24% | ||
| 6 Months | -4.35% | ||
| 1 Year | -20.18% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -71.12 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -66.24 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -65.68 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -40.04 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -6.10 | ||||
| 5.63 | ||||
| 102.75 | ||||
| - | ||||
| -15.80 | ||||
| -0.44 | ||||
| 5.63 | ||||
| 0.58 | ||||
| 110.54M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.50 | ||||
| 2.00 | ||||
| 0.12 | ||||
| 0.16 | ||||
| -120.10 | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -38.00 | ||||
| -3 064.50 | ||||
| -3 064.50 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 327.27K | ||||
| 0.03 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 5th May 2021 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 119.38K |
| Shares Outstanding | 34.01M |
| Trades Count | 580 |
| Dollar Volume | 1.81M |
| Avg. Volume | 618.41K |
| Avg. Weekly Volume | 163.00K |
| Avg. Monthly Volume | 225.10K |
| Avg. Quarterly Volume | 679.30K |
Aptorum Group Limited (NASDAQ: APM) stock closed at 2.64 per share at the end of the most recent trading day (a 3.53% change compared to the prior day closing price) with a volume of 120.26K shares and market capitalization of 89.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 39 people. Aptorum Group Limited CEO is Ian Huen.
The one-year performance of Aptorum Group Limited stock is -20.18%, while year-to-date (YTD) performance is 6.88%. APM stock has a five-year performance of %. Its 52-week range is between 1.16 and 14.23, which gives APM stock a 52-week price range ratio of 11.32%
Aptorum Group Limited currently has a PE ratio of -6.10, a price-to-book (PB) ratio of 5.63, a price-to-sale (PS) ratio of 102.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.24%, a ROC of -65.68% and a ROE of -71.12%. The company’s profit margin is -%, its EBITDA margin is -3 064.50%, and its revenue ttm is $327.27 Thousand , which makes it $0.03 revenue per share.
Of the last four earnings reports from Aptorum Group Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aptorum Group Limited’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Aptorum Group Limited is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Aptorum Group Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptorum Group Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptorum Group Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 20.39, ATR14 : 0.32, CCI20 : -157.24, Chaikin Money Flow : -0.23, MACD : -0.20, Money Flow Index : 60.64, ROC : -8.33, RSI : 37.62, STOCH (14,3) : 24.00, STOCH RSI : 0.51, UO : 39.02, Williams %R : -76.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptorum Group Limited in the last 12-months were:
Aptorum Group Limited
Aptorum Group Ltd is a pharmaceutical company. It is engaged in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The firm is also seeking therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
CEO: Ian Huen
Telephone: +44 2080929299
Address: 17 Hanover Square, London W1S 1BN, , GB
Number of employees: 39
